Company Overview - ADC Therapeutics SA (ADCT) is anticipated to report a year-over-year increase in earnings due to higher revenues for the quarter ended March 2025, with a consensus outlook indicating a quarterly loss of $0.38 per share, reflecting a +32.1% change from the previous year [1][3] - Expected revenues for ADC Therapeutics are projected at $18.15 million, which is a slight increase of 0.6% compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 8.33% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4] - The Most Accurate Estimate for ADC Therapeutics aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [6][8] - ADC Therapeutics currently holds a Zacks Rank of 3, making it challenging to predict a definitive earnings beat [11] Historical Performance - In the last reported quarter, ADC Therapeutics was expected to post a loss of $0.35 per share but actually reported a loss of $0.29, resulting in a surprise of +17.14% [12] - Over the past four quarters, the company has surpassed consensus EPS estimates two times [13] Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Cardiff Oncology (CRDF) is expected to report a loss of $0.19 per share for the same quarter, indicating a year-over-year change of +13.6% [17] - Cardiff Oncology's revenue is projected to be $0.17 million, down 19.1% from the previous year, but it has an Earnings ESP of 24.32% and a Zacks Rank of 2, suggesting a higher likelihood of beating the consensus EPS estimate [18]

Certara, Inc. (CERT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 5. On ...

The market expects Vertex Pharmaceuticals (VRTX) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 5, 2025, might help the stock move higher if these key number ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Stoke Therapeutics, Inc. (STOK) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the ...

Company Overview - Rhythm Pharmaceuticals, Inc. (RYTM) shares increased by 5.2% to $62.97 in the last trading session, with a notable trading volume, and have gained 10.2% over the past four weeks [1][2] - The rise in stock price is linked to positive investor expectations regarding the strong sales growth of its marketed product, Imcivree (setmelanotide) injection, which is approved for treating Bardet-Biedl syndrome [2] Financial Performance - The company is projected to report a quarterly loss of $0.69 per share, reflecting a year-over-year increase of 70.6%, while revenues are expected to reach $40.18 million, up 54.7% from the same quarter last year [3] - Despite the positive revenue growth expectations, the consensus EPS estimate has been revised 0.7% lower over the last 30 days, indicating a negative trend in earnings estimate revisions [4] Industry Context - Rhythm Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, where another company, Mirum Pharmaceuticals, Inc. (MIRM), saw a 2.2% increase in its stock price, but has returned -14.4% over the past month [4] - Mirum Pharmaceuticals is also facing a consensus EPS estimate change of -2.8% for its upcoming report, with a year-over-year change of +27.8% [5]

Company Performance - Humacyte, Inc. closed at $1.48, with a daily increase of +0.68%, underperforming the S&P 500's gain of 2.03% [1] - Over the past month, Humacyte's shares have decreased by 26.5%, compared to the Medical sector's loss of 8.57% and the S&P 500's loss of 5.07% [1] Earnings Expectations - The upcoming earnings report for Humacyte is anticipated to show an EPS of -$0.19, which represents a 34.48% increase from the same quarter last year [2] Analyst Estimates - Recent changes in analyst estimates for Humacyte indicate a positive outlook, reflecting analysts' confidence in the company's business performance and profit potential [3] - The Zacks Consensus EPS estimate has increased by 10.48% over the last 30 days, suggesting a favorable trend in analyst sentiment [5] Industry Context - Humacyte operates within the Medical - Biomedical and Genetics industry, which currently holds a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [6] - The Zacks Industry Rank measures the strength of industry groups, indicating that the top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1 [6]

Company Performance - CRISPR Therapeutics AG (CRSP) closed at $39.11, with a daily increase of +1.48%, underperforming the S&P 500's gain of 2.03% [1] - The company's stock has decreased by 1.63% over the past month, which is better than the Medical sector's decline of 8.57% and the S&P 500's drop of 5.07% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of -$1.27, reflecting an 11.19% improvement from the same quarter last year [2] - Revenue is anticipated to be $5.24 million, indicating a significant increase of 947.2% compared to the previous year’s quarter [2] Full Year Estimates - For the full year, analysts project an EPS of -$5.09 and revenue of $56.98 million, representing changes of -17.28% and +52.69% respectively from the prior year [3] Analyst Sentiment - Recent changes in analyst estimates suggest a positive outlook for CRISPR Therapeutics AG, indicating optimism regarding the company's business and profitability [4] - The Zacks Rank system, which reflects these estimate changes, currently rates CRISPR Therapeutics AG at 3 (Hold) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes CRISPR Therapeutics AG, has a Zacks Industry Rank of 79, placing it in the top 32% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

The market expects Alnylam Pharmaceuticals (ALNY) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60 in the latest trading session, marking a +0.8% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.67%. On the other hand, the Dow registered a gain of 1.07%, and the technology-centric Nasdaq increased by 2.5%.Coming into today, shares of the company had gained 5.9% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.The upcoming earnings release of Ginkgo Bioworks Holdi ...

Group 1 - Guardant Health (GH) is expected to report a year-over-year decline in earnings, with a projected loss of $0.61 per share, representing a -32.6% change, while revenues are anticipated to be $191.1 million, up 13.4% from the previous year [3][10] - The earnings report is scheduled for April 30, 2025, and could influence the stock price depending on whether the results exceed or fall short of expectations [2][12] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] Group 2 - The Most Accurate Estimate for Guardant Health is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -38.35%, suggesting a bearish sentiment among analysts [10][11] - Guardant Health has a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [11] - Historically, Guardant Health has beaten consensus EPS estimates three times over the last four quarters, but the last reported quarter showed a surprise miss of -24% [12][13] Group 3 - In comparison, Repligen (RGEN) is expected to post earnings of $0.35 per share for the same quarter, indicating a year-over-year increase of +25%, with revenues projected at $164.48 million, up 8.7% [17] - Repligen's consensus EPS estimate has been revised 0.4% lower in the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 3.77%, indicating a likelihood of beating the consensus [18]